Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $33.65 USD
Change Today +1.24 / 3.83%
Volume 434.8K
PRTA On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

prothena corp plc (PRTA) Key Developments

Prothena Corporation plc Announces Positive Results from a Phase 1 Single Ascending Dose Study of PRX002

Prothena Corporation plc announced positive results from a Phase 1 single ascending dose study of PRX002, a monoclonal antibody for the potential treatment of Parkinson's disease and other related synucleinopathies. PRX002 is the focus of a worldwide collaboration between Prothena and Roche. PRX002 was safe and well-tolerated, meeting the primary objective of the study. Further, results from this study showed that administration of PRX002 leads to mean reduction of free serum alpha-synuclein levels of up to 96%.

Prothena Corporation plc Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Earnings Guidance for Full Year of 2015

Prothena Corporation plc announced unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported total revenue of $2,013,000 against $167,000 a year ago. The increase was primarily due to $1.9 million and $50.3 million in collaboration revenue recognized in relation to the PRX002 collaboration with Roche in the fourth quarter and full year of 2014, respectively. Loss from operations was $13,105,000 against $10,702,000 a year ago. Loss before income taxes was $12,987,000 against $10,906,000 a year ago. Net loss was $13,110,000 against $11,054,000 a year ago. Basic and diluted net loss per share attributable to holders of ordinary shares was $0.48 against $0.52 per share a year ago. Net cash used in operating activities was $12.5 million. For the year, the company reported total revenue of $50,854,000 against $676,000 a year ago. Loss from operations was $6,649,000 against $40,427,000 a year ago. Loss before income taxes was $6,339,000 against $40,581,000 a year ago. Net loss was $7,150,000 against $40,996,000 a year ago. Basic and diluted net loss per share attributable to holders of ordinary shares was $0.29 against $2.20 per share a year ago. Net cash used in operating activities was $0.7 million. The company expects the full year 2015 net cash burn from operating activities to be $66 million, ending the year with approximately $225 million in cash (mid-point). The estimated full year 2015 net cash burn from operating is primarily driven by an estimated net loss of $77 to $83 million, which includes an estimated $9 million of non-cash share-based compensation expense.

Prothena Corporation plc to Report Q4, 2014 Results on Mar 05, 2015

Prothena Corporation plc announced that they will report Q4, 2014 results at 5:00 PM, GMT Standard Time on Mar 05, 2015

Prothena Corporation plc, Q4 2014 Earnings Call, Mar 05, 2015

Prothena Corporation plc, Q4 2014 Earnings Call, Mar 05, 2015

Prothena Corporation plc Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 09:00 AM

Prothena Corporation plc Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 09:00 AM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: Gene G. Kinney, Chief Scientific Officer and Head of Research & Development.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRTA:US $33.65 USD +1.24

PRTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PRTA.
View Industry Companies
 

Industry Analysis

PRTA

Industry Average

Valuation PRTA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 18.1x
Price/Book 3.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROTHENA CORP PLC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.